title: Estrogen suppression in males: metabolic effects.
abstract: We have shown that testosterone (T) deficiency per se is associated with marked catabolic effects on protein, calcium metabolism, and body composition in men independent of changes in GH or insulin-like growth factor I production. It is not clear,,however, whether estrogens have a major role in whole body anabolism in males. We investigated the metabolic effects of selective estrogen suppression in the male using a potent aromatase inhibitor, Arimidex (Anastrozole). First, a dose-response study of 12 males (mean age, 16.1 +/- 0.3 yr) was conducted, and blood withdrawn at baseline and after 10 days of oral Arimidex given as two different doses (either 0.5 or 1 mg) in random order with a 14-day washout in between. A sensitive estradiol (E2) assay showed an approximately 50% decrease in E2 concentrations with either of the two doses; hence, a 1-mg dose was selected for other studies. Subsequently, eight males (aged 15-22 yr; four adults and four late pubertal) had isotopic infusions of [(13)C]leucine and (42)Ca/(44)Ca, indirect calorimetry, dual energy x-ray absorptiometry, isokinetic dynamometry, and growth factors measurements performed before and after 10 weeks of daily doses of Arimidex. Contrary to the effects of T withdrawal, there were no significant changes in body composition (body mass index, fat mass, and fat-free mass) after estrogen suppression or in rates of protein synthesis or degradation; carbohydrate, lipid, or protein oxidation; muscle strength; calcium kinetics; or bone growth factors concentrations. However, E2 concentrations decreased 48% (P = 0.006), with no significant change in mean and peak GH concentrations, but with an 18% decrease in plasma insulin-like growth factor I concentrations. There was a 58% increase in serum T (P = 0.0001), sex hormone-binding globulin did not change, whereas LH and FSH concentrations increased (P < 0.02, both). Serum bone markers, osteocalcin and bone alkaline phosphatase concentrations, and rates of bone calcium deposition and resorption did not change. In conclusion, these data suggest that in the male 1) estrogens do not contribute significantly to the changes in body composition and protein synthesis observed with changing androgen levels; 2) estrogen is a main regulator of the gonadal-pituitary feedback for the gonadotropin axis; and 3) this level of aromatase inhibition does not negatively impact either kinetically measured rates of bone calcium turnover or indirect markers of bone calcium turnover, at least in the short term. Further studies will provide valuable information on whether timed aromatase inhibition can be useful in increasing the height potential of pubertal boys with profound growth retardation without the confounding negative effects of gonadal androgen suppression.
authors.affiliation: Nemours Research Programs at the Nemours Children's Clinic, Jacksonville, Florida 32207, USA. nmauras@nemours.org
authors.forename: N
authors.initials: N
authors.lastname: Mauras
authors.forename: K O
authors.initials: KO
authors.lastname: O'Brien
authors.forename: K O
authors.initials: KO
authors.lastname: Klein
authors.forename: V
authors.initials: V
authors.lastname: Hayes
mesh_terms: D000293:Adolescent; D000328:Adult; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000494:pharmacology*; D001823:Body Composition / Q000187:drug effects / Q000502:physiology; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D004958:Estradiol / Q000097:blood; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D006133:Growth Substances / Q000097:blood; D006728:Hormones / Q000097:blood; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D007651:Keto Acids / Q000097:blood; D007700:Kinetics; D016729:Leuprolide / Q000494:pharmacology; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D009570:Nitriles / Q000009:adverse effects / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D006133:Growth Substances; D006728:Hormones; D007651:Keto Acids; D009570:Nitriles; D011506:Proteins; D014230:Triazoles; D019382:Human Growth Hormone; D000077384:Anastrozole; D004958:Estradiol; C013082:alpha-ketoisocaproic acid; D016729:Leuprolide; D002118:Calcium